PDE4A and obesity due to melanocortin 4 receptor deficiency: PDE-4 inhibitors have been evaluated for the treatment of several diseases, including chronic obstructive pulmonary disease [82] and metabolic disorders such as T2DM, obesity and hypertension [83].